As part of the agreement, Quintiles also has acquired Bioglan Pharma Inc.'s rights to certain dermatology products now on the market in the United States, including the prescription product ADOXA(TM) (doxycycline) for the treatment of severe acne.

These products complement Quintiles' purchase of the North America commercialization license for Solaraze(TM) (diclofenac sodium) Gel, formerly held by Bioglan, in December 2001. Solaraze is a new class of topical treatment for the pre-cancerous skin condition actinic keratosis.

"The addition of Bioglan Pharma Inc.'s products, management team, infrastructure and capabilities further enhances the range of portfolio management solutions we can offer our customers," said Quintiles Transnational Chief Executive Officer Pam Kirby, Ph.D. "Bioglan Pharma Inc.'s sales force also will continue to provide support for the commercialization of Solaraze in the United States. Moreover, we are now in a position to plan our investments in product promotion to expand the sales of our specialty dermatology products."

Bioglan Pharma Inc., based in Malvern, Pa., has about 45 employees in the United States. Robert Moccia, president of Bioglan Pharma Inc., said: "Our management team is very pleased to be joining Quintiles and we are excited about the prospect of adding our expertise to Quintiles' service offerings. This is good news for our employees, for doctors who prescribe Bioglan Pharma Inc.'s dermatology products and for the patients who use them."

Moccia will report to Ron Wooten, president of Quintiles' PharmaBio Development group.
Quintiles Transnational is the world's leading provider of information, technology and services to bring new medicines to patients faster and improve healthcare. Headquartered near Research Triangle Park, North Carolina, Quintiles is a member of the S&P 500 and Fortune 1000. For more information visit the company's Web site at www.quintiles.com.

Information in this press release contains "forward-looking statements" about Quintiles that involve risks and uncertainties that could cause actual results to differ materially, including without limitation, our ability to integrate successfully the acquired assets with our current operations, the risk associated with entering into a new line of business resulting from the asset acquisition, the risk that PharmaBio transactions will not generate revenues, profit or return on investment at the rate or levels we anticipate, our ability to distribute backlog among project management groups and match demand to resources, our actual operating performance, our ability to maintain large client contracts or to enter into new contracts, changes in trends in the pharmaceutical industry, and liability risks associated with our business which could result in losses or indemnity to others not covered by insurance. Additional factors that could cause actual results to differ materially, including with respect to data products, are discussed in our recent filings with the Securities and Exchange Commission.